Advertisement
U.S. markets open in 6 hours 50 minutes

Arch Therapeutics, Inc. (ARTH)

Other OTC - Other OTC Delayed Price. Currency in USD
2.7000+0.3700 (+15.88%)
At close: 01:38PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.3300
Open2.4880
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.4880 - 2.7000
52 Week Range0.3900 - 18.0000
Volume1,196
Avg. Volume19,505
Market Cap12.804M
Beta (5Y Monthly)3.64
PE Ratio (TTM)N/A
EPS (TTM)-1.4000
Earnings DateMay 20, 2024 - May 24, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ARTH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ARCH THERAPEUTICS INC
    Analyst Report: Baxter International Inc.Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter offers tools to help patients with acute and chronic kidney failure, which it plans to spin off by mid-2024. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.
    Rating
    Fair Value
    Economic Moat
    8 days agoMorningstar
View more
  • GlobeNewswire

    Arch Therapeutics Provides Year End Operational Update

    Continued Strong Trends in Orders and Paid ClaimsFRAMINGHAM, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a year-end operational update, including key performance metrics related to the ongoing commercialization activities for the Company’s first product, AC5® Advanced Wound System (“AC5”). During its fourth fiscal quarter, the Company

  • GlobeNewswire

    Arch Therapeutics to Present AC5® Advanced Wound System at the 2023 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)

    AC5® Advanced Wound System to be Featured in the Hands-On Skills Lab for Clinicians and a Clinical Case Poster Demonstrating Utility in Treatment of Venous Leg UlcersFRAMINGHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that the Company’s first commercial product, AC5® Advanced Wound System (“AC5”), will be featured at the 2023 Symposium on Advanc

  • GlobeNewswire

    Arch Therapeutics Provides AC5® Commercialization Update

    Orders and Paid Claims Increasing Since Rollout of Reimbursement CodeFRAMINGHAM, Mass., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today provided a commercialization update on the Company’s first product, AC5® Advanced Wound System. Since the Centers for Medicare and Medicaid Services (“CMS”) established A2020, a Level II Healthcare Common Procedure Codi